Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Grand View Research | PRODUCT CODE: 1553681

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553681

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market is expected to be valued at USD 28.62 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

  • The antiviral drugs segment dominated the market in the global liver disease therapeutics market with a revenue share of 30.3% in 2023. The high incidence of hepatitis diseases contributes to the rise in liver disease cases.
  • The targeted therapy segment is expected to register the fastest CAGR of 7.2% over the forecast period, driven by the rising incidence of liver diseases and geriatric population globally.
  • The hepatitis segment dominated the global liver disease therapeutics market with a revenue share of 36.6% in 2023.
  • Non-alcoholic fatty liver disease (NAFLD) is expected to register the fastest growth over the forecast period with a CAGR of 6.6%. Segment growth is fueled by the increasing prevalence of obesity and associated fat accumulation in liver cells.
  • North America liver disease therapeutics market dominated the global liver disease therapeutics market with a revenue share of 38.4% in 2023.
  • Asia Pacific liver disease therapeutics market is expected to have the fastest growth in the forecast period with a CAGR of 7.4%.
Show more
Product Code: 978-1-68038-540-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Diseases Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
    • 3.3.3. Liver Diseases Therapeutics Market Analysis Tools
    • 3.3.4. Porter's Analysis
      • 3.3.4.1. Bargaining power of the suppliers
      • 3.3.4.2. Bargaining power of the buyers
      • 3.3.4.3. Threats of substitution
      • 3.3.4.4. Threats from new entrants
      • 3.3.4.5. Competitive rivalry
    • 3.3.5. PESTEL Analysis
      • 3.3.5.1. Political landscape
      • 3.3.5.2. Economic and Social landscape
      • 3.3.5.3. Technological landscape
      • 3.3.5.4. Environmental landscape
      • 3.3.5.5. Legal landscape

Chapter 4. Liver Disease Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Disease Therapeutics Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Antiviral Drugs
    • 4.3.1. Antiviral Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Vaccines
    • 4.4.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Immunosuppressants
    • 4.7.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Immunoglobulins
    • 4.8.1. Immunoglobulins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Corticosteroids
    • 4.9.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Other Products
    • 4.10.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Disease Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Hepatitis
    • 5.3.1. Hepatitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Autoimmune Diseases
    • 5.4.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 5.5.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Genetic Disorders
    • 5.7.1. Genetic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Diseases
    • 5.8.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Liver Disease Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. F. Hoffmann-La Roche Ltd
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Takeda Pharmaceutical Company Limited
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Gilead Sciences, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. Johnson & Johnson Services, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. Sanofi
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. AbbVie Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. GlaxoSmithKline PLC
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!